Abstract
Dyspepsia is a disease with one or more symptoms relating to abnormalities in gastroduodenal. One of the factors that influence dyspepsia is Helicobacter pylori (H. pylori). Clarithromycin-based triple therapy is recommended as first line eradication treatment. Resistance towards clarithromycin is increasing and causing eradication rates in Clarithromycin-based triple therapy to decrease. The purpose of this study was to determine the effectiveness of triple therapy variation on dyspepsia with H. pylori infection. Data was collected through literature searches on two different databases using the preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) 2020. This systematic review included all relevant articles from 2011-2021. Six studies met the inclusion criteria. The results showed that metronidazole-based triple therapy is effective in eradicating H. pylori due to its eradication rate surpassing the target rate of 80%. The highest eradication rates in intention-to-treat (ITT) and per-protocol (PP) were 94.3% and 93.5%, respectively. The best triple therapy composition is metronidazole-based triple therapy with 7 days of duration.References
Simadibrata M, Dadang K, Murdani M, Ari A, Syam F, Fauzi A, et al. Penatalaksanaan Dispepsia dan Infeksi Helicobacter pylori KONSENSUS NASIONAL Editor. Jakarta; 2014.
Talley NJ, Cook DR. Functional Dyspepsia. In: Essential Medical Disorders of the Stomach and Small Intestine. Cham: Springer International Publishing; 2019. p. 155–72.
Pramono L, Syam A. Recent Updates of Helicobacter pylori Infection: from Epidemiology Study to Guideline Issues. The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy. 2014;15(1).
Carroll K, Butel J, Morse S, Mietzner T. Jawetz, Melnick & Adelberg’s Medical Microbiology. 27th ed. New York: McGraw-Hill Education; 2016.
Uman LS. Systematic reviews and meta-analyses. Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l’Academie canadienne de psychiatrie de l’enfant et de l’adolescent. 2011 Feb;20(1):57–9.
Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;71.
Sarkeshikian SS, Iranikhah A, Ghadir MR. Azithromycin based triple therapy versus standard clarithromycin based triple therapy in eradication of Helicobacter pylori infection in Iran: a randomized controlled clinical trial. The Turkish Journal of Gastroenterology. 2013 Feb 1;24(1):10–4.
Hajaghamohammadi A, Safiabadi Tali SH, Samimi R, Oveisi S, Kazemifar AM. Low Dose Furazolidone for Eradication of H- pylori Instead of Clarithromycin: A Clinical Trial. Global Journal of Health Science. 2014 Aug 31;7(1).
Khoshnood A, Hakimi P, Salman-Roghani H, Reza Mirjalili M. Replacement of clarithromycin with azithromycin in triple therapy regimens for the eradication of Helicobacter pylori: A randomized clinical trial. Journal of medicine and life. 2014 Jun 15;7(2):254–9.
Gungor G, Baglıcakoglu M, Kayacetin E, Biyik M, Ucar R, Goktepe H, et al. Current Status of Five Different Regimens for Empiric First-Line Helicobacter pylori Eradication in Turkey. Digestion. 2015;92(2):55–9.
Nishizawa T, Maekawa T, Watanabe N, Harada N, Hosoda Y, Yoshinaga M, et al. Clarithromycin Versus Metronidazole as First-line Helicobacter pylori Eradication. Journal of Clinical Gastroenterology. 2015 Jul;49(6):468–71.
Adachi T, Matsui S, Watanabe T, Okamoto K, Okamoto A, Kono M, et al. Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for pylori Oncology. 2017;93(1):15–9.
Prasertpetmanee S, Mahachai V, Vilaichone R. Improved Efficacy of Proton Pump Inhibitor - Amoxicillin - Clarithromycin Triple Therapy for Helicobacter pylori Eradication in Low Clarithromycin Resistance Areas or for Tailored Therapy. Helicobacter. 2013 Aug;18(4):270–3.
Kim TH, Park JM, Cheung DY, Oh JH. Comparison of 7- and 14-Day Eradication Therapy for Helicobacter pylori with First- and Second-Line Regimen: Randomized Clinical Trial. Journal of Korean Medical Science. 2020;35(5).
Onyekwere CA. Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori eradication therapy: Report of an efficacy study. World Journal of Gastroenterology. 2014;20(13):3615.
Leow AH ‐R., Azmi AN, Loke M, Vadivelu J, Graham DY, Goh K. Optimizing first line 7‐day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better? Journal of Digestive Diseases. 2018 Nov 8;19(11):674–7.
Choi HS. Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. World Journal of Gastroenterology. 2012;18(19):2377.
Wang J, Zhang G, Hu X, Liu Y, Bao Z, Huang Y. Two-week triple therapy has a higher Helicobacter pylori eradication rate than 1-week therapy: A single-center randomized study. Saudi Journal of Gastroenterology. 2015;21(6):355.
Li B, Lan X, Wang L, Zhao J, Ding J, Ding H, et al. Proton-pump inhibitor and amoxicillin-based triple therapy containing clarithromycin versus metronidazole for Helicobacter pylori: A meta-analysis. Microbial Pathogenesis. 2020 May;142:104075.
Marques AT, Vítor JMB, Santos A, Oleastro M, Vale FF. Trends in helicobacter pylori resistance to clarithromycin: From phenotypic to genomic approaches. Vol. 6, Microbial Genomics. Microbiology Society; 2020.
Loghmari H, Bdioui F, Bouhlel W, Melki W, Hellara O, ben Chaabane N, et al. Clarithromycin versus metronidazole in first-line Helicobacter pylori eradication. Prospective randomized study of 85 Tunisian adults. La Tunisie medicale. 2012 Jan;90(1):31–5.
Cammarota G, Tursi A, Papa A, Montalto M, Veneto G, Cuoco L, et al. Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. Alimentary Pharmacology & Therapeutics. 1996 Oct;10(6):997–1000.
Silva FM, Eisig JN, Teixeira ACS, Barbuti RC, Navarro-Rodriguez T, Mattar R. Short-term triple therapy with azithromycin for Helicobacter pylori eradication: Low cost, high compliance, but low efficacy. BMC Gastroenterology. 2008 Dec 29;8(1):20.
Mohammadi M, Attaran B, Malekzadeh R, Graham DY. Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran. Digestive diseases and sciences. 2017;62(8):1890–6.
Alba C, Blanco A, Alarcón T. Antibiotic resistance in Helicobacter pylori. Current Opinion in Infectious Diseases. 2017 Oct;30(5):489–97.
Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology. 2018 Nov;155(5):1372-1382.e17.
Bujanda L, Nyssen OP, Vaira D, Saracino IM, Fiorini G, Lerang F, et al. Antibiotic Resistance Prevalence and Trends in Patients Infected with Helicobacter pylori in the Period 2013–2020: Results of the European Registry on H. pylori Management (Hp-EuReg). Antibiotics. 2021 Sep 1;10(9).
All articles submitted by the author and published in the Journal of Research in Pharmacy and Pharmaceutical Sciences, are fully copyrighted by the publication of JJournal of Research in Pharmacy and Pharmaceutical Sciences under the Creative Commons Attribution-NonCommercial 4.0 International License by technically filling out the copyright transfer agreement and sending it to the publisher
Note :
The author can include in separate contractual arrangements for the non-exclusive distribution of rich versions of journal publications (for example: posting them to an institutional repository or publishing them in a book), with the acknowledgment of their initial publication in this journal.
Authors are permitted and encouraged to post their work online (for example: in an institutional repository or on their website) before and during the submission process because it can lead to productive exchanges, as well as earlier and more powerful citations of published works. (See Open Access Effects).